Earnings summaries and quarterly performance for Immunocore Holdings.
Executive leadership at Immunocore Holdings.
Board of directors at Immunocore Holdings.
KP
Kristine Peterson
Detailed
Director
PS
Professor Sir John Bell
Detailed
Chairman of the Board of Directors
PS
Professor Sir Peter Ratcliffe
Detailed
Director
RK
Ranjeev Krishana
Detailed
Director
RP
Robert Perez
Detailed
Director
RS
Roy S. Herbst, M.D., Ph.D.
Detailed
Director
SK
Siddharth Kaul
Detailed
Director
WP
William Pao, M.D., Ph.D.
Detailed
Director
Research analysts who have asked questions during Immunocore Holdings earnings calls.
ES
Eric Schmidt
Cantor Fitzgerald & Co.
6 questions for IMCR
Also covers: ADCT, AGIO, BEAM +11 more
RS
Rajan Sharma
Goldman Sachs Group, Inc.
6 questions for IMCR
Also covers: ARGX, AUTL, AZN +6 more
Jack Allen
Robert W. Baird & Co.
5 questions for IMCR
Also covers: ACAD, ALLO, BLUE +8 more
JC
Jonathan Chang
Leerink Partners
5 questions for IMCR
Also covers: ADAP, GMAB, KPTI +10 more
Michael Schmidt
Guggenheim Securities
5 questions for IMCR
Also covers: ADAP, ADCT, ARVN +20 more
TV
Tyler Van Buren
TD Cowen
5 questions for IMCR
Also covers: ADVM, ALLO, ARGX +13 more
Justin Zelin
BTIG, LLC
4 questions for IMCR
Also covers: BCAB, CASI, GLMD +9 more
Michael Yee
Jefferies
4 questions for IMCR
Also covers: ABBV, ALLO, AMGN +19 more
NQ
Naureen Quibria
Capital One Securities
4 questions for IMCR
Also covers: CMRX, GLYC
Patrick Trucchio
H.C. Wainwright & Co.
4 questions for IMCR
Also covers: ALT, ARWR, ATAI +13 more
EL
Elias Lenard
JPMorgan Chase & Co.
3 questions for IMCR
Graig Suvannavejh
Mizuho Securities
3 questions for IMCR
Also covers: ADAP, ADVM, ALEC +12 more
PL
Peter Lawson
Barclays PLC
3 questions for IMCR
Also covers: ADAP, ARVN, BPMC +15 more
AD
Ahu Demir
Ladenburg Thalmann & Co. Inc.
2 questions for IMCR
Also covers: CLRB, CYCC, SLRX
AJ
Avantika Joshi
Mizuho Securities
2 questions for IMCR
Also covers: BTAI, RAIN
Ethan Markowski
Needham & Company
2 questions for IMCR
Also covers: TSHA
Gil Blum
Needham & Company
2 questions for IMCR
Also covers: ABSI, AUTL, CELC +9 more
JS
James Shin
Analyst
2 questions for IMCR
Also covers: ABBV, AMGN, AUTL +7 more
Jeff Jones
Oppenheimer & Co. Inc.
2 questions for IMCR
Also covers: ABEO, CLRB, CMMB +8 more
Paul Jeng
Guggenheim Partners
2 questions for IMCR
Also covers: ADAP, BPMC, INCY +2 more
Sean Laaman
Morgan Stanley & Co.
2 questions for IMCR
Also covers: ACAD, ARGX, AXSM +8 more
Adam Ferrari
J.P. Morgan
1 question for IMCR
Also covers: ALKS, BMRN, HALO
AD
Ahu Demir
Ladenburg Thalmann
1 question for IMCR
Also covers: AADI, CYCC, SLRX
AA
Albert Agustinus
Leerink Partners
1 question for IMCR
Also covers: KPTI, NVCR, RVMD
DD
David Dai
UBS Group AG
1 question for IMCR
Also covers: IOVA, KURA, SMMT +2 more
EF
Eva Fortea
Wells Fargo
1 question for IMCR
Also covers: KNSA
Faisal Khurshid
Leerink Partners
1 question for IMCR
Also covers: ABCL, ANIP, ASND +7 more
JH
Jeff Hung
Morgan Stanley
1 question for IMCR
Also covers: ACAD, ALEC, BHVN +10 more
JF
Jessica Fye
JPMorgan Chase & Co.
1 question for IMCR
Also covers: ALKS, ALNY, AMRN +23 more
RO
Romeo O'Connor
Trondkepen
1 question for IMCR
RO
Romy O'Connor
VLK
1 question for IMCR
Also covers: VALN
XD
Xiaochuan Dai
UBS
1 question for IMCR
Also covers: KURA, NBTX, SNDX
Recent press releases and 8-K filings for IMCR.
Immunocore Holdings Reports Q4 and Full-Year 2025 Financial Results and Provides Pipeline Update
IMCR
Earnings
Guidance Update
New Projects/Investments
- Immunocore Holdings reported total net KIMMTRAK revenue of $400.0 million for FY 2025 and $104.5 million for Q4 2025, with the product achieving 15 consecutive quarters of growth.
- The company recorded a net loss of ($35.5 million) and a net loss per share of ($0.71) for FY 2025.
- For its pipeline, the TEBE-AM Phase 3 trial for 2L+ advanced cutaneous melanoma is expected to complete enrollment in 1H 2026, with topline data anticipated as early as 2H 2026.
- Immunocore is also advancing other Phase 3 trials for melanoma (ATOM, PRISM-MEL-301) and expanding its pipeline into additional tumor types and non-oncology areas such as HIV, HBV, and Type 1 diabetes.
3 days ago
Immunocore Reports Strong 2025 KIMMTRAK Revenue and Pipeline Progress
IMCR
Earnings
Guidance Update
New Projects/Investments
- Immunocore reported $400 million in net revenue from KIMMTRAK for the full year 2025, representing a 29% increase over the prior year.
- The company maintains a strong financial position with approximately $864 million in cash and marketable securities as of year-end 2025.
- Significant pipeline progress includes three ongoing Phase III trials: TEBE-AM (second-line cutaneous melanoma) with enrollment completion expected in the first half of 2026 and top-line data as early as the second half of 2026; ATOM (adjuvant uveal melanoma) expanding to U.S. sites in 2026; and PRISM-MEL-301 (first-line cutaneous melanoma) which selected the 160 microgram dose in December 2025.
- For 2026, Immunocore anticipates moderating growth for KIMMTRAK sales, with R&D expenses expected to increase modestly year-over-year.
3 days ago
Immunocore Holdings Reports Strong 2025 KIMMTRAK Revenue and Pipeline Progress
IMCR
Earnings
Guidance Update
New Projects/Investments
- Immunocore Holdings reported $400 million in net revenue from KIMMTRAK for the full year 2025, representing a 29% increase over the prior year.
- The company's balance sheet remains strong with approximately $864 million in cash and marketable securities as of year-end 2025, an increase of over $40 million from the previous year.
- Key pipeline advancements include TEBE-AM (second-line cutaneous melanoma) enrollment completion on track for the first half of 2026, with top-line data expected as early as the second half of 2026.
- Immunocore is expanding its pipeline into new therapeutic areas, with the first patient in a Phase I study for its Type 1 Diabetes program expected to be dosed in the first half of 2026, and data from its HIV program anticipated in the second half of 2026.
- For 2026, the company expects moderating growth for KIMMTRAK and anticipates R&D expenses to increase modestly year-over-year, with only incremental increases in SG&A.
3 days ago
Immunocore Reports Q4 and Full Year 2025 Results, Highlights Pipeline Progress
IMCR
Earnings
Guidance Update
New Projects/Investments
- Immunocore reported $400 million in net revenue from KIMMTRAK for the full year 2025, marking a 29% year-over-year increase, and maintained a strong balance sheet with approximately $864 million in cash and marketable securities at year-end.
- The company anticipates moderating growth for KIMMTRAK in 2026 due to significant market penetration, while expecting R&D expenses to increase modestly and SG&A expenses to see incremental increases for commercial preparations.
- Immunocore is advancing three Phase III oncology trials, with TEBE-AM (second-line cutaneous melanoma) on track for enrollment completion in the first half of 2026 and top-line data expected as early as the second half of 2026.
- The company is expanding its platform into infectious disease and autoimmune diseases, with the first patient in the Phase I Type 1 diabetes program expected to be dosed in the first half of 2026.
3 days ago
Immunocore Holdings plc Reports Q4 and Full Year 2025 Financial Results
IMCR
Earnings
Guidance Update
New Projects/Investments
- Immunocore reported KIMMTRAK net sales of $104.5 million for Q4 2025 and $400.0 million for the full year 2025, with expectations of moderating revenue growth in 2026.
- The company ended 2025 with cash, cash equivalents, and marketable securities totaling $864.2 million as of December 31, 2025.
- For Q4 2025, Immunocore reported a net loss of $30.1 million and a basic and diluted loss per share of $0.60. The full year 2025 net loss was $35.5 million, with a loss per share of $0.71.
- Key clinical pipeline updates include anticipated TEBE-AM enrollment completion in the first half of 2026 with topline data expected as early as the second half of 2026, and PRAME franchise Phase 1/2 data to be presented in the second half of 2026.
3 days ago
Immunocore Provides 2026 Pipeline and Commercial Growth Outlook
IMCR
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Immunocore reported 14 consecutive quarters of growth for Kimmtrak, with 30% revenue growth in the first three quarters of 2025, and expects continued growth in 2026 through US penetration and global expansion, potentially increasing the eligible patient population from 1,000 to 6,000 with new indications.
- The company anticipates key data readouts in the second half of 2026 for the Phase 3 TEBE-AM trial in second-line cutaneous melanoma, with enrollment completion expected in the first half of 2026.
- Other significant pipeline milestones for 2026 include data for PRAME in ovarian and non-small cell lung cancer, and further dose escalation data for the HIV compound MTAV, both expected in the second half of 2026.
- Immunocore ended 2025 with approximately $860 million in unaudited cash, demonstrating a strong financial position to fund ongoing Phase 3 trials and pipeline advancement.
Jan 14, 2026, 4:15 PM
Immunocore Provides Update on Kimmtrak Performance, Pipeline Progress, and Financial Position
IMCR
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Immunocore's commercial product, Kimmtrak, achieved 30% revenue growth in the first three quarters of 2025 and has demonstrated 14 consecutive quarters of growth.
- The company is expanding Kimmtrak's potential with two ongoing Phase 3 trials: TEBE-AM for second-line cutaneous melanoma (enrollment completion H1 2026, data as early as H2 2026) and ADAM for adjuvant uveal melanoma, which could increase the eligible patient population from 1,000 to 6,000 patients.
- Immunocore is advancing its pipeline with the PRAME asset (brenetafusp) in a Phase 3 trial for first-line cutaneous melanoma (enrollment anticipated by 2027) and exploring it in ovarian and non-small cell lung cancer, with data for these indications expected in H2 2026.
- The company ended 2025 with approximately $860 million in cash on the balance sheet, an increase from $820 million at the same time last year, supporting its investment in Phase 3 studies and pipeline advancement.
Jan 14, 2026, 4:15 PM
Immunocore Provides 2026 Outlook and Pipeline Updates at J.P. Morgan Healthcare Conference
IMCR
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Immunocore reported 30% revenue growth for KIMMTRAK in 2025, marking 14 consecutive quarters of growth, and anticipates increasing the eligible patient population from 1,000 to 6,000 patients through two ongoing Phase III trials for metastatic uveal melanoma (MUM) and adjuvant uveal melanoma (ADAM), with TEBE-AM enrollment completing in H1 2026 and data as early as H2 2026.
- The company is advancing a diversified pipeline, with key data readouts expected in H2 2026 for PRAME (brenetafusp) in ovarian and non-small cell lung cancer, and for the HIV program (MTAV). The Phase III PRISM-MEL trial for PRAME in first-line cutaneous melanoma is targeting enrollment completion by 2027, and a Type 1 diabetes trial is set to begin in H1 2026.
- Immunocore ended 2025 with approximately $860 million in cash, an increase from $820 million at the end of 2024, supporting its data-driven R&D investments and disciplined SG&A.
Jan 14, 2026, 4:15 PM
Immunocore Outlines 2026 Milestones and Preliminary Year-End Cash
IMCR
Guidance Update
New Projects/Investments
- Immunocore reported a preliminary unaudited year-end cash position of $864 million as of December 31, 2025.
- The company anticipates moderate revenue growth in 2026 for KIMMTRAK , with key milestones including completing enrollment in the Phase 3 TEBE-AM trial in 1H 2026 and an earliest topline readout window in 2H 2026.
- In 2H 2026, Immunocore expects data from Phase 1/2 combinations of brenetafusp in ovarian cancer and from Phase 1/2 monotherapy and combinations in NSCLC.
- Other significant pipeline milestones for 2026 include the first patient dosed in a Phase 1 trial for IMC-S118AI in type 1 diabetes in 1H 2026, data from the Phase 1 HIV trial in 2H 2026, and an IND/CTA for a CD1a x PD1 trial in atopic dermatitis in 2H 2026.
Jan 13, 2026, 12:00 PM
Immunocore Holdings plc Announces 2026 Strategic Priorities
IMCR
New Projects/Investments
Guidance Update
- Immunocore Holdings plc outlined its 2026 strategic priorities, focusing on growing KIMMTRAK in melanoma, expanding beyond melanoma into other tumor types, and realizing growth opportunities beyond oncology in infectious and autoimmune diseases.
- Key clinical milestones for 2026 include the anticipated completion of enrollment for the TEBE-AM Phase 3 trial in previously treated cutaneous melanoma in 1H 2026, with topline data expected as early as 2H 2026.
- The company plans to present Phase 1/2 data for brenetafusp combinations in ovarian and lung cancer, initial data for IMC-P115C in multiple solid tumors, and additional Phase 1 HIV data in 2H 2026.
- In autoimmune diseases, Immunocore expects to dose the first patient in a Phase 1 type 1 diabetes trial in 1H 2026 and submit a clinical trial application for a second autoimmune candidate in 2H 2026.
- Immunocore reported preliminary unaudited cash, cash equivalents, and marketable securities of approximately $864 million as of December 31, 2025.
Jan 9, 2026, 12:11 PM
Fintool News
In-depth analysis and coverage of Immunocore Holdings.
Quarterly earnings call transcripts for Immunocore Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more